Wednesday, July 8, 2026

pharma · Patency of the Ductus Arteriosus · Atopic Dermatitis · CNTB

S.L

S.L is a pharma organization headquartered in SAN DIEGO, CA, EU. It trades on NYSE under ticker CNTB. Primary therapeutic focus areas include Patency of the Ductus Arteriosus, Atopic Dermatitis, Chronic Rhinosinusitis Wi

SAN DIEGO, CA, EU HQ
Public company Type
CNTB · NYSE Ticker
Company details
Status
Public
HQ
SAN DIEGO, CA, EU
Programs
15
Drugs
11
Patents
179
Clinical program

CBP-201-CN004

Phase 1 · mab · Healthy Adult Subjects

CBP-201-CN004 for Healthy Adult Subjects is a Phase 1 program (mab) at S.L with 1 ClinicalTrials.gov record(s).

← All S.L projects Phase 1 mab completed

Internal code CBP-201-CN004

Full intelligence profile for this program is being prepared.

At a glance

Sponsor
S.L
Phase
Phase 1
Modality
mab
Indication
Healthy Adult Subjects
Status
completed
Trials
1